| ||||||||||||||||||||||||||||||||||
The following text is from an archived Red Book® edition and may not reflect current recommendations or information. To view the current edition, click here.
Section 3. Summaries of Infectious Diseases
PRION DISEASES
Transmissible Spongiform Encephalopathies 1
Clinical Manifestations
Etiology
Epidemiology
Diagnostic Tests
Treatment
Isolation of the Hospitalized Patient
Control Measures
CLINICAL MANIFESTATIONS: Transmissible spongiform encephalopathies (TSEs), or prion diseases, constitute a group of rare, rapidly progressive, universally fatal neurodegenerative syndromes of humans and animals that are characterized by neuronal degeneration, spongiform change, gliosis, and accumulation of an abnormal protease-resistant amyloid protein (protease-resistant prion protein [PrPres] or scrapie prion protein [PrPsc]) distributed diffusely throughout the brain and sometimes also in discrete plaques. Pathologic involvement of other organ systems has been reported in animal TSEs, but not in humans.
Top
Next
The human TSEs include several diseases: Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker disease, fatal familial insomnia, kuru, and variant CJD (vCJD). Classic CJD can be sporadic (approximately 85% of cases), familial (approximately 15%), or iatrogenic (<1%). Iatrogenic CJD has been acquired through injection of cadaveric pituitary hormones (growth hormone and human gonadotropin), dura mater allografts, corneal transplantation, and instrumentation of the brain at neurosurgery or depth-electrode electroencephalographic recording. In 1996, an outbreak of vCJD linked to exposure to tissues from bovine spongiform encephalopathy (BSE)-infected cattle was reported in the United Kingdom. The best known TSEs affecting animals are scrapie of sheep, BSE, and a chronic wasting disease of North American deer and elk.
Creutzfeldt-Jakob disease manifests as a dementing syndrome with progressive defects in memory, personality, and other higher cortical functions in approximately two thirds of affected people. Approximately one third of patients have cerebellar dysfunction, including ataxia and dysarthria. Iatrogenic CJD
Related Article
Red Book 2003 2003: 106-116.